I think the jury's still out with the newer drugs. As I mentioned in another thread, the TITAN study for ADT+Erleada to treat mCSPC finished after 4 1/2 years with a large percentage of participants not having reached castrate resistance yet (and more than half still alive), even though many of them had had metastatic cancer for a while before the study started.

(The previous approach was to start on something different like Zytiga for mCSPC, and hold off on the newer -lutamides until the cancer developed castrate resistance, but TITAN showed it was more effective to start on Apalutmide right away, both for delaying progression and for increasing overall survival.)

I'm at 3 1/2 years on ADT and Erleada so far and still have undetectable PSA (I've never had chemo, but have had radiation). Like many here, I'm enrolled in the international IRONMAN study to track my progress, so we're the ones who will provide the data for the next round of treatments and best practices.